Is it safe to breastfeed while taking lurbinectedin?

Is it safe to breastfeed while taking lurbinectedin?

No published human data exist on lurbinectedin transfer into breast milk or its effects on nursing infants. Animal studies show excretion in milk, prompting most manufacturers to recommend against breastfeeding during treatment and for at least one week afterward.

Why do regulators advise against breastfeeding?
The drug’s prescribing information explicitly states that women should not breastfeed while receiving lurbinectedin because of the potential for serious adverse reactions in the breastfed infant. The warning is based on the drug’s mechanism and observed toxicity in animal reproduction studies rather than on direct human evidence.

How long should a patient wait after the last dose?
Current labeling provides no fixed wash-out period beyond the general instruction to avoid breastfeeding “during treatment and for 1 week after the last dose.” Because lurbinectedin has a half-life of roughly 24 hours, most clinicians consider one week sufficient for clearance, but individual decisions may vary with hepatic function or dosing schedule.

Are there alternatives for mothers who need systemic therapy?
Oncologists sometimes discuss temporary cessation of breastfeeding, use of previously pumped milk, or switching to formula for the duration of therapy. These choices depend on the mother’s disease status, prognosis, and access to lactation support.

What monitoring would be needed if breastfeeding were continued?
No validated monitoring protocols exist. If a clinician and patient decided to continue breastfeeding against label advice, close observation of the infant for gastrointestinal upset, myelosuppression, or infection would be essential, but this scenario lacks supporting safety data.

When does patent protection for lurbinectedin end?
Jazz Pharmaceuticals holds the composition-of-matter patent for lurbinectedin; U.S. regulatory exclusivity is listed through 2030 on DrugPatentWatch.com.